Objective
To evaluate the usefulness of screening investigations in patients with neurofibromatosis type 1 (NF1).
Design
Clinical and screening data were retrospectively collected from a case series of patients with NF1. Screening investigations included an opthalmologic consultation, chest x-ray film, abdominal ultrasonography, cerebral imaging, and analysis of urinary catecholamine levels. Clinical features and complications of patients with NF1 were compared with those of the Neurofibromatoses Institute Clinical Research Program and of the Southeast Wales study patients.
Setting
Ambulatory care in a referral center.
Patients
Between 1988 and 1992, 152 patients classified as having NF1 according to the criteria of the National Institutes of Health Consensus Development Conference Statement were studied.
Main Outcome Measure
Complications requiring therapeutic action detected using screening investigations vs clinical examination.
Results
Systemic chest x-ray films were taken of 134 Patients, and intrathoracic nodules thought to be neurofibromas were discovered in 2 patients. Ninety-three asymptomatic patients had cerebral imaging performed, which showed optic pathway glioma in 12 patients. Abdominal ultrasonography was performed on 62 asymptomatic patients, results of which showed internal neurofibromas in 4 patients. In 2 of these patients, abdominal surgery was performed. Eighty-three patients without hypertension had 24-hour urinary specific catecholamine levels analyzed, which were within the normal range. Clinical features and complications were not different from other large clinical studies. Nearly 400 systematic investigations were performed without clinical orientation, detecting 21 abnormalities. In only 2 cases, these discoveries led to therapeutic action. On the other hand, 22 complications requiring treatment were detected by clinical examination.
Conclusion
Clinical follow-up seems to be more beneficial than systematic investigations in patients with NF1.
Arch Dermatol. 1996;132:1333-1336
Ophthalmological manifestations in segmental neurofibromatosis type 1
Ruggieri et al.
Br J Ophthalmol 2004;88:1429-1433.
ABSTRACT
| FULL TEXT
Clinical Risk Factors for Mortality in Patients With Neurofibromatosis 1: A Cohort Study of 378 Patients
Khosrotehrani et al.
Arch Dermatol 2003;139:187-191.
ABSTRACT
| FULL TEXT
Quality-of-Life Impairment in Neurofibromatosis Type 1: A Cross-sectional Study of 128 Cases
Wolkenstein et al.
Arch Dermatol 2001;137:1421-1425.
ABSTRACT
| FULL TEXT
A clinical assessment of neurofibromatosis type 1 (NF1) and segmental NF in northern Finland
POYHONEN
J. Med. Genet. 2000;37:43e-43.
FULL TEXT
Use of ""unidentified bright objects"" on MRI for diagnosis of neurofibromatosis 1 in children
DeBella et al.
Neurology 2000;54:1646-1651.
ABSTRACT
| FULL TEXT
Use of the National Institutes of Health Criteria for Diagnosis of Neurofibromatosis 1 in Children
DeBella et al.
Pediatrics 2000;105:608-614.
ABSTRACT
| FULL TEXT
Neurological complications of neurofibromatosis type 1 in adulthood
Creange et al.
Brain 1999;122:473-481.
ABSTRACT
| FULL TEXT
Screening in Neurofibromatosis Type 1
O'Connor and Murphy
Arch Dermatol 1997;133:655-656.
ABSTRACT
Screening Evaluations in Neurofibromatosis Type I
Journal Watch Dermatology 1997;1997:11-11.
FULL TEXT
